Merck Q2 Revenue Beats Expectations, Keytruda Drives Growth but Full-Year Earnings Guidance Sharply Cut
N.R. Finch
Merck's Q2 revenue hit $16.61 billion, up 5% and above Wall Street consensus, but a $5.7 billion one-time charge from the Terns acquisition nearly halved full-year EPS guidance — the real question has shifted from 'how well does it sell' to whether the pipeline can bridge the 2028 patent cliff.
Where is the core contradiction in this report?
Revenue came in at $16.61 billion, roughly $250 million above consensus; adjusted EPS loss of $0.13 beat the expected $0.27 loss — on the surface, a clean beat.
But the quarter posted a net loss of $1.34 billion, versus net income of $4.43 billion a year ago. This means → the swing from profit to loss is dramatic and the "beat" headline alone is misleading.
The loss was driven by a $5.7 billion one-time charge from the Terns Pharmaceuticals acquisition — a biotech focused on blood-cancer drugs — amounting to $2.31 per share.
In plain terms = the drugs sold better than expected, but a massive acquisition bill flipped the bottom line to red. Investors need to separate "operating strength" from "one-time check."
How is Keytruda actually performing?
Keytruda — Merck's flagship immuno-oncology drug — posted global sales of $8.37 billion, up 5% and above analysts' $8.07 billion estimate.
The new subcutaneous formulation, QLEX, contributed $463 million. This means → a formulation launched less than a year ago already accounts for roughly 5.5% of total Keytruda sales — a rapid uptake.
CFO Caroline Litchfield said QLEX has reached a "double-digit" share of U.S. Keytruda volume, with a target of 30%–40% penetration by end of 2027.
In plain terms = QLEX takes about one minute to inject versus 30 minutes for IV infusion — easier for patients and clinics, hence the fast switch. Its patent protection runs to 2039, making it Merck's key hedge against the 2028 patent expiry.
How did the rest of the portfolio perform?
Winrevair — a treatment for pulmonary arterial hypertension, or abnormally high pressure in lung blood vessels — posted $588 million in sales, up 75% year-on-year.
HPV vaccine Gardasil came in at $1.17 billion, slightly above the $1.15 billion estimate. Traditional vaccines for measles, mumps, rubella, and varicella fell 3% to $592 million, which Merck attributed to softer overall U.S. vaccine demand.
Diabetes drugs Januvia and Janumet dropped 31% to $429 million. This means → the post-patent generic impact is unmistakable — and it is exactly the scenario the market fears for Keytruda's future.
Animal health posted $1.78 billion, up 8% and slightly above estimates — a steady ballast business.
Why does the full-year guidance show "revenue up, earnings halved"?
Full-year revenue guidance was raised to $66.3–$67.3 billion, with the midpoint roughly matching the $66.8 billion consensus.
But full-year adjusted EPS was cut from $5.04–$5.16 to $2.66–$2.76, below the $2.79 analyst estimate.
Nearly all the cut traces to acquisition costs: Terns one-time charge of $2.31/share + financing costs of roughly $0.12 + ongoing Terns pipeline development expenses — total dilution of approximately $2.43/share.
In plain terms = strip out the acquisition charges and Merck's operating earnings power is intact. But shareholders' earnings were genuinely diluted, so the stock-price pressure is rational.
How does Merck plan to navigate the 2028 patent cliff?
Keytruda's core patents expire in 2028, opening the door to biosimilar competition. Januvia's 31% sales collapse offers a real-world preview of what patent expiry looks like.
Merck is pursuing three paths: QLEX's patent extends to 2039, buying transition time; the ADC — antibody-drug conjugate, a technology that delivers chemotherapy directly to tumor cells — Sac-TMT, developed with CSPC, has pivotal data expected in October; and Winrevair's supplemental application for newly diagnosed PAH patients is under FDA review with a target date of late September.
This means → Q3–Q4 this year is a concentrated pipeline-validation window. The October ADC readout and the September Winrevair decision will directly shape how the market prices Merck's "post-Keytruda era."
This reflects a broader industry dynamic: big-pharma valuations increasingly depend not on how well current drugs sell, but on whether new products can fill the gap before patents expire.
Content is for reference only, not financial advice.